Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apellis Pharmaceuticals (Nasdaq: APLS) has announced the approval of equity inducement awards for three new employees, effective February 3, 2025. The grants, made outside the company's 2017 Stock Incentive Plan but under the 2020 Inducement Stock Incentive Plan, consist of 7,805 restricted stock units (RSUs). These equity awards were approved in compliance with Nasdaq Listing Rule 5635(c)(4).
The RSUs will vest over four years, with 25% vesting on the first anniversary of the grant date and an additional 25% vesting annually thereafter, contingent upon continued employment.
Apellis Pharmaceuticals (Nasdaq: APLS) ha annunciato l'approvazione di premi per indurre l'equità per tre nuovi dipendenti, a decorrere dal 3 febbraio 2025. I premi, concessi al di fuori del Piano di Incentivazione Azionaria del 2017 dell'azienda ma nell'ambito del Piano di Incentivazione Azionaria del 2020, consistono in 7.805 unità azionarie vincolate (RSUs). Questi premi azionari sono stati approvati in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
Le RSUs matureranno nel corso di quattro anni, con il 25% che maturerà al primo anniversario della data di concessione e un ulteriore 25% che maturerà annualmente successivamente, a condizione di continuare l'impiego.
Apellis Pharmaceuticals (Nasdaq: APLS) ha anunciado la aprobación de premios por inducir capital para tres nuevos empleados, con efecto a partir del 3 de febrero de 2025. Las concesiones, realizadas fuera del Plan de Incentivos de Acciones de 2017 de la empresa, pero bajo el Plan de Incentivos de Acciones por Inducimiento de 2020, constan de 7,805 unidades de acciones restringidas (RSUs). Estos premios de capital fueron aprobados en cumplimiento con la Regla de Listado 5635(c)(4) de Nasdaq.
Las RSUs se consolidarán a lo largo de cuatro años, con un 25% consolidándose en el primer aniversario de la fecha de concesión y un 25% adicional consolidándose anualmente a partir de entonces, dependiendo de la continuación del empleo.
Apellis Pharmaceuticals (나스닥: APLS)는 2025년 2월 3일부터 효력이 발생하는 세 명의 신입 직원에게 주식 유도 상을 승인했다고 발표했습니다. 이 상은 회사의 2017 주식 인센티브 계획 외부에서 수여되지만 2020 유도 주식 인센티브 계획에 따라 7,805개의 제한 주식 단위(RSU)로 구성됩니다. 이러한 주식 상은 나스닥 상장 규칙 5635(c)(4)에 따라 승인되었습니다.
RSU는 4년에 걸쳐 소유권이 확정되며, 첫 번째 기념일에 25%가 확정되며 이후 매년 추가로 25%가 확정되며, 고용 상태 유지에 따라 달라집니다.
Apellis Pharmaceuticals (Nasdaq: APLS) a annoncé l'approbation de primes d'incitation à l'équité pour trois nouveaux employés, à compter du 3 février 2025. Les allocations, faites en dehors du Plan d'Incentives en Actions de 2017 de l'entreprise mais dans le cadre du Plan d'Incentives en Actions de 2020, consistent en 7 805 unités d'actions restreintes (RSUs). Ces primes d'équité ont été approuvées conformément à la règle de cotation 5635(c)(4) de Nasdaq.
Les RSUs seront acquises sur une période de quatre ans, avec 25 % acquises à la première date anniversaire de la date d'attribution et 25 % supplémentaires acquises chaque année par la suite, sous réserve de maintien de l'emploi.
Apellis Pharmaceuticals (Nasdaq: APLS) hat die Genehmigung von Aktienprämien für drei neue Mitarbeiter bekannt gegeben, die ab dem 3. Februar 2025 wirksam werden. Die Zuwendungen, die außerhalb des Aktienanreizplans von 2017 des Unternehmens, aber im Rahmen des Aktienanreizplans von 2020 vergeben werden, bestehen aus 7.805 eingeschränkten Aktieneinheiten (RSUs). Diese Eigenkapitalprämien wurden gemäß der Nasdaq-Listing-Regel 5635(c)(4) genehmigt.
Die RSUs werden über einen Zeitraum von vier Jahren vollständig, wobei 25 % am ersten Jahrestag des Gewährungsdatums und weitere 25 % jährlich danach, unter der Bedingung der fortgesetzten Beschäftigung, vesten.
- Successful recruitment of three new employees with equity-based compensation alignment
- Potential dilution of existing shareholders through new RSU issuance
WALTHAM, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that the company approved the grant of equity awards to three new employees with a grant date of February 3, 2025, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2020 Inducement Stock Incentive Plan) and material to the employees’ acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
The employees received 7,805 restricted stock units (RSUs). Each RSU will vest as to
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.
Apellis Forward-Looking Statement
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors discussed in the “Risk Factors” section of Apellis’ Annual Report on Form 10-K with the Securities and Exchange Commission on February 27, 2024 and Quarterly Report on Form 10-Q filed on November 5, 2024 and the risks described in other filings that Apellis may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Media Contact:
Lissa Pavluk
media@apellis.com
617.977.6764
Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178
FAQ
How many RSUs did Apellis Pharmaceuticals (APLS) grant in February 2025?
What is the vesting schedule for APLS's February 2025 RSU grants?
Under which plan were the February 2025 APLS equity inducement awards granted?
What Nasdaq rule did Apellis comply with for the February 2025 equity grants?
